# C_2015207EN.01001601.xml

| 24.6.2015 | EN | Official Journal of the European Union | C 207/16 |
| --- | --- | --- | --- |

24.6.2015

EN

Official Journal of the European Union

C 207/16

---

Prior notification of a concentration

(Case M.7559 — Pfizer/Hospira)

(Text with EEA relevance)

(2015/C 207/14)

| 1. | On 15 June 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Pfizer Inc. (‘Pfizer’) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Hospira Inc. (‘Hospira’), both of the US, by way of purchase of shares. |
| --- | --- |

1.

On 15 June 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Pfizer Inc. (‘Pfizer’) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of Hospira Inc. (‘Hospira’), both of the US, by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | Pfizer is a global research based biomedical and pharmaceutical company active in discovering, developing, manufacturing, marketing and selling innovative medicines for humans. |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Pfizer is a global research based biomedical and pharmaceutical company active in discovering, developing, manufacturing, marketing and selling innovative medicines for humans.

| — | Hospira is global provider of injectable drugs and infusion technologies, with a broad portfolio of generic, branded and biosimilar medicines for humans. |
| --- | --- |

—

Hospira is global provider of injectable drugs and infusion technologies, with a broad portfolio of generic, branded and biosimilar medicines for humans.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7559 — Pfizer/Hospira), to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7559 — Pfizer/Hospira), to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---